Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Has Average Price Target of $19.40

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been given a consensus recommendation of “Hold” by the eight ratings firms that are currently covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold recommendation. The average 1 year price target among brokerages that have covered the stock in the last year is $19.40.

Several equities research analysts have weighed in on TBPH shares. JonesTrading cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Weiss Ratings upgraded Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, August 17th. Zacks Research cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 7th. HC Wainwright cut Theravance Biopharma from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $15.00 to $17.00 in a research note on Tuesday, July 7th. Finally, BTIG Research restated a “neutral” rating on shares of Theravance Biopharma in a research report on Thursday, September 24th.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total transaction of $226,737.42. Following the completion of the sale, the senior vice president directly owned 213,476 shares of the company’s stock, valued at approximately $3,635,496.28. This trade represents a 5.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 7.65% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds have recently bought and sold shares of TBPH. Squarepoint Ops LLC purchased a new position in shares of Theravance Biopharma during the second quarter worth about $302,000. Groupe la Francaise purchased a new position in Theravance Biopharma in the second quarter valued at about $510,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Theravance Biopharma during the second quarter worth $1,071,000. GTS Securities LLC purchased a new position in shares of Theravance Biopharma during the 2nd quarter worth approximately $430,000. Finally, Hsbc Holdings PLC increased its position in Theravance Biopharma by 14.4% during the second quarter. Hsbc Holdings PLC now owns 49,428 shares of the biopharmaceutical company’s stock worth $843,000 after buying an additional 6,224 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Stock Performance

Shares of TBPH stock opened at $17.03 on Friday. The stock has a market capitalization of $884.18 million, a P/E ratio of 16.86 and a beta of 0.25. The firm’s 50 day moving average is $17.02 and its 200 day moving average is $16.77. Theravance Biopharma has a 12 month low of $13.08 and a 12 month high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). The firm had revenue of $20.73 million for the quarter, compared to analysts’ expectations of $22.49 million. Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. On average, equities analysts predict that Theravance Biopharma will post 1.56 EPS for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for respiratory disease and other serious conditions. The company’s work centers on therapies designed to address unmet needs in areas such as chronic obstructive pulmonary disease (COPD) and related respiratory disorders.

Its principal commercial product is YUPELRI (revefenacin), an inhaled long-acting muscarinic antagonist used as a once-daily maintenance treatment for COPD. YUPELRI is commercialized in collaboration with Viatris.